Axsome Therapeutics Stock News

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Axsome has one pending approval and two pending NDAs coming up in 2023. They are adequately funded, if not very strongly.

Historic 2022 inflation lifted energy and value stocks while sinking growth plays. The post 100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles appeared first on Investor's

Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well.

These mid-cap biotechs are solid long-term choices.

These businesses are growing and can be excellent places to make a sizable investment right now.

Revenue prospects look promising for both of these biotech companies.

Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.

Stocks usually go down during recessions, but long-term investors can still come out on top.

Axsome's revenue story is just getting started.

Right now is the perfect time to put your money to work.

An economic downturn shouldn't hurt these stocks.

The stock market witnessed an upward trend last month, a continuation from October.

Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.

These stocks' tailwinds should continue blowing in the new year.